Polymerizable Compound, Compound, and Method for Producing Boranophosphate Oligomer

ABSTRACT

Provided is a polymerizable compound represented by a Formula E-1 or Formula E-2 shown in the description. In Formula E-1 or Formula E-2, R1 represents an alkoxy group, —NRN2, a hydroxy group, an aryl group, or an alkyl group, wherein RN each independently represents a hydrogen atom or an alkyl group having 1 to 10 carbon atoms; n represents an integer from 1 to 5; R3 represents a hydrogen atom, an acetyl group, a phenoxyacetyl group, a pivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoyl group, a triphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, a trimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or a cyanoethoxymethyl group; and X represents a structure represented by any one of Formula B-1 to Formula B-5 shown in the description.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.16/349,438 filed May 13, 2019, which is the U.S. national stage ofPCT/JP2017/040469 filed Nov. 9, 2017, which claims the priority benefitof Japan Application No. 2016-221656 on Nov. 14, 2016, the respectivedisclosures of which are hereby incorporated by reference in theirentirety for all purposes herein.

BACKGROUND Technical Field

The present disclosure relates to a polymerizable compound, a compound,and a method of producing a boranophosphate oligomer.

Background Art

An antisense molecule having a complementary base sequence to a targetnucleic acid forms a duplex with the target nucleic acid and proteinproduction from the target nucleic acid can be inhibited. The antisensemolecule receives attention as an effective medicine for gene treatment,since the antisense molecule directly act on a disease related gene,when the disease-related gene is selected as the target nucleic acid.

The antisense molecule (nucleic acid oligomer) is mainly required tohave cell membrane permeability, nuclease resistance, chemical stabilityin the body (for example, under the environment of pH 7.4), and aproperty of forming stable duplex with a specific base sequence, fromthe viewpoint of effectively inhibiting production of target protein.

As the antisense molecule, for example, an oligomer having a structurein which at least a portion is substituted by a phosphorothioate bondamong phosphodiester structures of nucleic acid oligomers, an oligomerhaving a structure in which at least a portion is substituted by aboranophosphate structure (hereinafter, referred to as “boranophosphateoligomer”) among phosphodiester structures of nucleic acid oligomers,and the like are known, and there have been many extensive researchexamples so far and the oligomers have been put to practical use even asmedicine.

The boranophosphate structure refers to a structure in which one ofnon-bridging oxygen atoms in a phosphodiester structure is substitutedby a borano group (—BH₃).

The boranophosphate oligomer has advantages of having high nucleaseresistance, high RNA interference (RNAi) activity, higher affinity forRNA than DNA, a low nonspecific interaction with proteins, andapplicability to boron neutron capture therapy (BNCT).

A conventional method of producing a boranophosphate oligomer mayinclude methods described in J. Am. Chem. Soc. 1990,112,9000,Tetrahedron Lett. 1997, 38, 4957, J. Am. Chem. Soc. 1998, 120, 9417,Tetrahedron Lett. 1998, 39, 3899, T. Angew. Chem. Int. Ed. 2009, 48,496-499, T. RSC Adv. 2015, 5, 2392-2395, and Tetrahedron Lett. 2012, 53,4361-4364.

SUMMARY

Since in a boranophosphate oligomer, a phosphorus atom is an asymmetriccenter, the boranophosphate oligomer contains monomer units which aretwo kinds of stereoisomers (Rp isomer, Sp isomer) having differentproperties from each other.

Thus, development of a method of stereoselectively synthesizing theisomers is required.

In a method of synthesizing a boranophosphate oligomer described in J.Am. Chem. Soc. 1990, 112, 9000, Tetrahedron Lett. 1997, 38, 4957, J. Am.Chem. Soc. 1998, 120, 9417, or Tetrahedron Lett. 1998, 39, 3899, therewas a problem in that steric control of a phosphorus atom is notpossible.

A method of synthesizing a boranophosphate oligomer described in T.Angew. Chem. Int. Ed. 2009, 48, 496-499 or RSC Adv. 2015, 5, 2392-2395is useful in that steric control of a phosphorus atom is possible;however, there was a problem in that a side reaction occurred in a basemoiety protected by a protecting group upon boronation of a phosphorusatom.

By the above-described side reaction, synthesis of a boranophosphateoligomer containing a nucleoside having only a thymine (T) structure ora uracil (U) structure as a base is possible, but it was difficult tosynthesize a boranophosphate oligomer containing a nucleoside having abase having an amino group (—NH2) such as an adenine (A) structure, acytosine (C) structure, or a guanine (G) structure.

In a method of synthesizing a boranophosphate oligomer described inTetrahedron Lett. 2012, 53, 4361-4364, a protecting group of a basemoiety is removed together with an asymmetric auxiliary group of aphosphorus atom, under acidic conditions.

Thus, since no side reaction of a base moiety occurs upon boronationdescribed above, it is possible to stereoselectively synthesize aboranophosphate oligomer containing a nucleoside having a base having anamino group such as an adenine structure, cytosine structure, or guaninestructure, as well as a thymine structure or uracil structure.

In the present disclosure, stereoselectively synthesizing aboranophosphate oligomer refers to performing synthesis undercontrolling whether any one of two stereoisomers (Rp isomer or Spisomer) having the phosphorus atom as an asymmetric center is includedfor each monomer unit (a nucleotide unit in which one of thenon-bridging oxygen atoms of a phosphodiester structure is substitutedwith a borano group (—BH₃)).

In the method of synthesizing a boranophosphate oligomer according toTetrahedron Lett. 2012, 53, 4361-4364, the asymmetric auxiliary grouphas a tertiary carbon atom and a steric hindrance by the asymmetricauxiliary group is large, in order to enable deprotection under acidicconditions.

Thus, there was a problem in that reactivity of a polymerizable compoundis low and stereoselectivity of a condensation reaction is reduced, forexample, about 1 to 2%.

Due to the above-mentioned problems, according to a method ofsynthesizing a boranophosphate oligomer related to Tetrahedron Lett.2012, 53, 4361-4364, for example, it was difficult to synthesize a longchain oligomer such as a decamer or higher oligomer.

As a result of intensive studies, the present inventors found that thepolymerizable compound according to the present disclosure is highlyreactive and allows stereoselective synthesis of an oligomer (forexample, a boranophosphate oligomer), regardless of whether a base in anucleoside has an amino group.

The monomer according to the present disclosure has no tertiary carbonatom described above, is highly reactive due to small steric hindrance,and allows synthesis of a long chain oligomer of, for example, a decameror higher oligomer. Also, since a protecting group of a base moiety isremoved together with an asymmetric auxiliary group of a phosphorusatom, under an acidic condition, for example, in the case of DNAsynthesis, the monomer is considered to allow stereoselective synthesisof a boranophosphate oligomer in which each of four base species of A,T, C, and G is freely combined, regardless of whether a base in anucleoside has an amino group.

In addition, the compound according to the present disclosure is a novelcompound which is an intermediate of synthesis of the boranophosphateoligomer.

In addition, according to the method of producing a boranophosphateoligomer according to the present disclosure, it has been found that itis possible to synthesize a long chain oligomer of, for example, adecamer or higher oligomer, and also, it is possible tostereoselectively synthesize a boranophosphate oligomer in which apolymerizable compound containing a nucleoside in which a base has anamino group and a polymerizable compound containing a nucleoside inwhich a base has no amino group are freely combined.

An object of the present invention is to provide a polymerizablecompound which is highly reactive and allows stereoselective synthesisof a boranophosphate oligomer, regardless of whether a base in anucleoside has an amino group.

In addition, another object of the present invention is to provide anovel compound.

Further, another object of the present invention is to provide a methodof producing a boranophosphate oligomer, which has high yield andstereoselectivity, and allows stereoselective synthesis of aboranophosphate oligomer, regardless of whether a base in a nucleosidehas an amino group.

As means for solving the above problems, the following embodiments areincluded.

<1>

A polymerizable compound represented by the following Formula A-1 orFormula A-2.

In Formula A-1 or Formula A-2, R¹ represents an electron-donating group;n represents an integer from 1 to 5; R² represents a hydrogen atom, ahalogen atom, or —OR^(O), wherein R^(O) represents a hydrogen atom, analkyl group, or a protecting group of a hydroxy group; R³ represents ahydrogen atom or a protecting group of a hydroxy group; and X representsa structure represented by any one of Formula B-1 to Formula B-5.

In Formula B-1 to Formula B-5, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; each of R^(pC),R^(pA), and R^(pG) represents a protecting group that is removed underan acidic condition; R^(pC2) represents a hydrogen atom or an alkylgroup; R^(pG2) represents a protecting group; R^(pG3) represents aprotecting group that is removed under an acidic condition, or ahydrogen atom; and a wavy line (

) represents a binding site to another structure.

<2>

A compound including a structural unit represented by the followingFormula T-1 and a structural unit represented by the following FormulaD-1 or Formula D-2.

In Formula T-1, R² represents a hydrogen atom, a halogen atom, or—OR^(O); wherein R^(O) represents a hydrogen atom, an alkyl group, or aprotecting group of a hydroxy group; Z represents a structurerepresented by any one of Formula B-6 to Formula B-9; and each of * and** represents a binding site with another structure.

In Formula D-1 or Formula D-2, R¹ represents an electron-donating group;n represents an integer from 1 to 5; R² represents a hydrogen atom, ahalogen atom, or —OR^(O), wherein R^(O) represents a hydrogen atom, analkyl group, or a protecting group of a hydroxy group; R³ represents ahydrogen atom or a protecting group of a hydroxy group; X represents astructure represented by any one of Formula B-1 to Formula B-5; TfOrepresents a triflate anion; and a black circle (●) represents a bindingsite with another structure.

In Formula B-1 to Formula B-5, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; each of R^(pC),R^(pA), and R^(pG) represents a protecting group that is removed underan acidic condition; R^(pC2) represents an alkyl group; R^(pG2)represents a protecting group; R^(pG3) represents a protecting groupthat is removed under an acidic condition or a hydrogen atom; and a wavyline (

) represents a binding site to another structure.

In Formula B-6 to Formula B-9, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; R^(C), R^(A), andR^(G) represent a hydrogen atom; and a wavy line (

) represents a binding site to another structure.

<3>

A compound described in <2>, further including one or both structuralunits represented by the following Formula C-1 or Formula C-2.

In Formula C-1 or Formula C-2, R² represents a hydrogen atom, a halogenatom, or —OR^(O); R^(O) represents a hydrogen atom, an alkyl group, or aprotecting group of a hydroxy group; Z represents a structurerepresented by any one of Formula B-6 to Formula B-9; and each of ** anda black circle (●) represents a binding site with another structure.

In Formula B-6 to Formula B-9, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; each of R^(C),R^(A), and R^(G) represents a hydrogen atom; and a wavy line (

) represents a binding site to another structure.

<4>

A method of producing a boranophosphate oligomer, including a step ofcondensing the polymerizable compound described in <1>.

According to an embodiment of the present invention, there can beprovided a polymerizable compound which is highly reactive and allowsstereoselective synthesis of a boranophosphate oligomer, regardless ofwhether a base in a nucleoside has an amino group.

In addition, according to another embodiment of the present invention, anovel compound is provided.

Further, according to another embodiment of the present invention, therecan be provided a method of producing a boranophosphate oligomer, whichhas high stereoselectivity and yield, and allows stereoselectivesynthesis of a boranophosphate oligomer, regardless of whether a base ina nucleoside has an amino group.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows HPLC charts showing results of reverse phase HPLC of (A) asynthesis reaction solution (crude) of (Rp)-T_(B)T [(Rp)-24a] and (B) asynthesis reaction solution (crude) of (Sp)-T_(B)T [(Sp)-24a].

FIG. 2 shows HPLC charts showing results of reverse phase HPLC of (C) asynthesis reaction solution (crude) of (Rp)-dC_(B)T [(Rp)-24b] and (D) asynthesis reaction solution (crude) of (Sp)-dC_(B)T [(Sp)-24b].

FIG. 3 shows is HPLC charts showing results of reverse phase HPLC of (E)a synthesis reaction solution (crude) of (Rp)-dA_(B)T [(Rp)-24c] and (D)a synthesis reaction solution (crude) of (Sp)-dA_(B)T [(Sp)-24c].

FIG. 4 shows HPLC charts showing results of reverse phase HPLC of (G) asynthesis reaction solution (crude) of (Rp)-dA_(B)T [(Rp)-24c] and (H) asynthesis reaction solution (crude) of (Sp)-dA_(B)T [(Sp)-24c].

FIG. 5 shows HPLC charts showing results of reverse phase HPLC of (I) asynthesis reaction solution (crude) of (Rp)-dG_(B)T [(Rp)-24d] and (J) asynthesis reaction solution (crude) of (Sp)-dG_(B)T [(Sp)-24d].

FIG. 6 shows HPLC charts showing results of reverse phase HPLC of (K) asynthesis reaction solution (crude) of all-(Rp)-d (C_(B)A_(B)G_(B)T)[25] and (L) a synthesis reaction solution (crude) of all-(Sp)-d(C_(B)A_(B)G_(B)T) [26].

FIG. 7 shows HPLC charts showing results of reverse phase HPLC of (M) apurified product of all-(Rp)-d (C_(B)A_(B)G_(B)T) [25] and (N) apurified product of all-(Sp)-d (C_(B)A_(B)G_(B)T) [26].

FIG. 8 shows HPLC charts showing results of reverse phase HPLC of (O) asynthesis reaction solution (crude) ofall-(Sp)-d(G_(B)T_(B)(A_(B)C_(B)T_(B))₃T) [27] and (P) a purifiedproduct of all-(Sp)-d(G_(B)T_(B)(A_(B)C_(B)T_(B))₃T) [27].

FIG. 9 shows HPLC charts showing results of reverse phase HPLC of (Q) asynthesis reaction solution (crude) ofall-(Sp)-d(C_(B)A_(B)G_(B)T_(B))₂(CBABGB)T[28] and (R) a synthesisreaction solution (crude) of all-(Rp)-d(C_(B)A_(B)G_(B)T_(B))₂(CBABGB)T[29].

DESCRIPTION OF EMBODIMENTS

Hereinafter, the present disclosure will be described in detail.

In addition, the description “xx to yy” herein represents a numericalvalue including xx and yy.

In addition, in the present disclosure, “% by mass” and “% by weight”are synonymous and “parts by mass” and “part by weight” are synonymous.

In addition, in the present disclosure, a combination of two or morepreferred embodiments is a more preferred embodiment.

In the present disclosure, regarding a representation of a group in acompound represented by a formula, when “substituted or unsubstituted”is not described and the group can further have a substituent, not onlyan unsubstituted group but also a substituted group is included, unlessotherwise specified. For example, in the formula, when it is describedthat “R represents an alkyl group”, it means that “R represents anunsubstituted alkyl group or a substituted alkyl group”.

The word “step” herein is included in the term, not only in the casewhere the step is an independent step, but also even in the case wherethe step cannot be clearly distinguished from other steps, when anintended purpose of the step is achieved.

Hereinafter, the present disclosure will be described in detail.

(Polymerizable Compound)

The polymerizable compound according to the present disclosure is acompound represented by the following Formula A-1 or Formula A-2.

It is preferred that the polymerizable compound according to the presentdisclosure is a polymerizable compound for forming a boranophosphateoligomer.

In Formula A-1 or Formula A-2, R¹ represents an electron-donating group;n represents an integer of 1 to 5; R² represents a hydrogen atom, ahalogen atom, or —OR^(O); R^(O) represents a hydrogen atom, an alkylgroup, or a protecting group of a hydroxy group; R³ represents ahydrogen atom or a protecting group of a hydroxy group; and X representsa structure represented by any one of Formula B-1 to Formula B-5.

In Formula B-1 to Formula B-5, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; each of R^(pC),R^(pA), and R^(pG) represents a protecting group that is removed underacidic conditions; R^(pC2) represents an alkyl group; R^(pG2) representsa protecting group; R^(pG3) represents a protecting group that isremoved under an acidic condition or a hydrogen atom; and a wavy line (

) represents a binding site to another structure.

In Formula A-1 or Formula A-2, R¹ represents an electron-donating group,and preferably an alkoxy group, —NR^(N) ₂, a hydroxy group, an arylgroup, or an alkyl group, more preferably an alkoxy group, still morepreferably an alkoxy group having 1 to 4 carbon atoms, and particularlypreferably a methoxy group.

R^(N) each independently represents a hydrogen atom or an alkyl grouphaving 1 to 10 carbon atoms.

In Formula A-1 or Formula A-2, n represents an integer of 1 to 5,preferably an integer of 1 to 3, and more preferably 1.

When n is 2 or more, a plurality of R¹ may be identical or differentfrom each other.

In Formula A-1 or Formula A-2, R² represents a hydrogen atom, a halogenatom, or —OR^(O).

Examples of the halogen atom of R² include a fluorine atom, a chlorineatom, a bromine atom, and an iodine atom, and a fluorine atom ispreferred.

R^(O) represents a hydrogen atom, an alkyl group, or a protecting groupof a hydroxy group, and as a protecting group of a hydroxy group, forexample, it is possible to use a protecting group conventionally knownas a protecting group used for protecting the hydroxy group at2-position of a ribose structure commonly used in the synthesis of RNAor its derivative, reference can be also made to protecting groupsdescribed in publications such as Green, et al., Protective Groups inOrganic Synthesis, 3rd Edition, 1999, John Wiley & Sons, Inc., andexamples thereof include an acetyl group, a phenoxyacetyl group, apivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoylgroup, a triphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, atrimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethylgroup, and a cyanoethoxymethyl group, and preferably a4,4′-dimethoxytrityl (DMTr) group.

R³ represents a hydrogen atom or a protecting group of a hydroxy group,and as a protecting group of a hydroxy group, reference can be made toprotecting groups described in publications such as Green, et al.,Protective Groups in Organic Synthesis, 3rd Edition, 1999, John Wiley &Sons, Inc., and examples thereof include an acetyl group, aphenoxyacetyl group, a pivaloyl group, a benzyl group, a 4-methoxybenzylgroup, a benzoyl group, a triphenylmethyl group, a 4,4′-dimethoxytrityl(DMTr) group, a 4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group,a trimethylsilyl group, a cyanomethoxymethyl group, a2-(cyanoethoxy)ethyl group, and a cyanoethoxymethyl group, andpreferably a 4,4′-dimethoxytrityl (DMTr) group.

In Formula A-1 or Formula A-2, X represents a structure represented byany one of Formula B-1 to Formula B-5, Formula B-1 corresponds to athymine structure or uracil structure, Formula B-2 corresponds to acytosine structure, Formula B-3 corresponds to an adenine structure, andFormula B-4 and Formula B-5 correspond to a guanine structure,respectively.

In addition, the thymine structure, the uracil structure, the cytosinestructure, the adenine structure, and the guanine structure include eachstructure having a substituent.

In Formula B-1 to Formula B-5, it is preferred that R^(T) represents ahydrogen atom, an alkyl group, an alkenyl group, or an alkynyl group,and a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, analkenyl group having 2 to 4 carbon atoms, or an alkynyl group having 2to 4 carbon atoms is preferred.

Each of R^(pC), R^(pA), and R^(pG) represent a protecting group that isremoved under acidic conditions, reference can be made to protectinggroups described in publications such as Green, et al., ProtectiveGroups in Organic Synthesis, 3rd Edition, 1999, John Wiley & Sons, Inc.,for example, a tert-butoxycarbonyl group, a benzyloxycarbonyl group, a4,4′-trimethoxytrityl (TMTr) group, a 4,4′-dimethoxytrityl (DMTr) group,a 4-methoxytrityl (MMTr) group, or 4-methoxybenzyloxycarbonyl (MCBz)group is preferred, and from a viewpoint of reducing steric hindranceand improving reactivity of a monomer, 4-methoxybenzyloxycarbonyl (MCBz)group is more preferred.

R^(pC2) represents a hydrogen atom or an alkyl group, preferably analkyl group having 1 to 4 carbon atoms, and more preferably a methylgroup.

R^(pG2) represents a protecting group, and as the protecting group, forexample, it is possible to use a known protecting group of a hydroxygroup without limitation, reference can be also made to protectinggroups described in publications such as Green, et al., ProtectiveGroups in Organic Synthesis, 3rd Edition, 1999, John Wiley & Sons, Inc.,and examples thereof include an acetyl group, a phenoxyacetyl group, apivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoylgroup, a triphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, atrimethylsilyl group, a trimethylsilylethyl group, a cyanomethoxymethylgroup, a 2-(cyanoethoxy)ethyl group, and a cyanoethoxymethyl group, andpreferably a trimethylsilylethyl group.

In addition, as R^(pG2), a protecting group that is removed under anacidic condition is preferred.

R^(pG3) represents a protecting group or a hydrogen atom that is removedunder acidic conditions in R^(pG) described above, and examples of theprotecting group include the same protecting group as those removedunder an acidic condition, and the same applies to a preferredembodiment thereof.

(Method of Producing a Polymerizable Compound)

Hereinafter, an example of the method of producing a polymerizablecompound according to the present disclosure will be described. However,the present disclosure is not limited thereto.

The polymerizable compound according to the present disclosure can besynthesized, for example, according to the following Scheme 1.

In the following Scheme 1, Et₃N is triethylamine.

In the following Scheme 1, (Rp)or(Sp)-20a-d is a compound represented byFormula A-1 or Formula A-2.

In Scheme 1, R¹, n, R², R³, and X have the same meaning as R¹, n, R², R³and X in Formula A-1 or Formula A-2, respectively, and the same appliesto a preferred embodiment thereof.

Compound 9a-d in Scheme 1 can be synthesized by using for example,thymidine, uridine, cytidine, adenosine, or guanosine as a raw material.

Compound (4S,5R)-18 in Scheme 1 can be synthesized, for example,according to the following Scheme 2.

In the following Scheme 2, Me is a methyl group, MMTrCl is4-methoxytrityl chloride, Et₃N is triethylamine, SO₃—Py is apyridine-sulfur trioxide complex, DCA is dichloroacetic acid, and PCl₃is phosphorus trichloride.

In addition, though the following Scheme 2 uses L-proline as a startingmaterial, compound (4R,5S)-18 can be synthesized by performing similarsynthesis using D-proline as a starting material.

(Method of Producing Boranophosphate Oligomer)

A method of producing a boranophosphate oligomer according to thepresent disclosure is a method of producing a boranophosphate oligomer,the method including a step of condensing a polymerizable compoundaccording to the present disclosure (hereinafter, also referred to as“condensation step”).

Hereinafter, an example of the method of producing a boranophosphateoligomer according to the present disclosure will be described. However,the present disclosure is not limited thereto.

<Condensation Step>

A condensation step in the present disclosure follows, for example, thefollowing Scheme 3.

In Scheme 3, R¹, n, R², R³, and X have the same meaning as R¹, n, R²,R³, and X in Formula A-1 or Formula A-2, respectively, and the sameapplies to a preferred embodiment thereof.

In addition, in Scheme 3, Z represents a structure represented by anyone of Formula B-6 to Formula B-9 described later.

In Scheme 3, deprotection of R³ is performed in Compound 27 loaded on asolid support. The deprotection of R³ is performed, for example, underacidic conditions.

Subsequently, an oligomer chain is extended by repeating a condensationreaction and deprotection of an asymmetric auxiliary group, a protectinggroup of a base, and R³, using the polymerizable compound and anactivator. Deprotection of the asymmetric auxiliary group and theprotecting group of a base is performed under an acidic condition. Byusing a protecting group that is removed under acidic conditions as R³,it is possible to perform deprotection of R³ simultaneously with thedeprotection of the asymmetric auxiliary group and the protecting groupof a base.

In Scheme 3, though the polymerizable compound 20a-d and compound 21(CMPT, N-(cyanomethyl)pyrrolidinium triflate) which is an activator areused, the activator is not limited thereto and can be changed.

After H-phosphonate oligomer 23 is formed, boronation is performed,thereby boranophosphate oligomer 24a-d is obtained.

In Scheme 3, though a synthesis method by a solid phase method is shown,it is possible to perform synthesis by a liquid phase method by the samescheme.

From a viewpoint of stereoselectivity and reaction rate, it is preferredto perform synthesis by a solid phase method.

In Scheme 3, details of an extension reaction of an oligomer chain areshown in the following Scheme 4.

In Scheme 4, R¹, n, R², R³, and X each independently have the samemeaning as R¹, n, R², R³, and X in Formula A-1 or Formula A-2, and thesame applies to a preferred embodiment thereof.

n represents an integer of 0 to 100, preferably an integer of 1 to 100,more preferably an integer of 9 to 100, and still more preferably aninteger of 11 to 100.

In Scheme 4, TfO (OTf) represents a triflate anion, and Z represents astructure represented by any one of Formula B-6 to Formula B-9 describedlater.

In Scheme 4, (Rp) or (Sp)-20a-d which is the polymerizable compoundaccording to the present disclosure is bonded to a hydroxy group at5′-position of a sugar structure at the end of H-phosphonate substitutednucleotide in the presence of an activator 21 and forms an intermediate28. Thereafter, an asymmetric auxiliary group from the intermediate 28,a protecting group of a base, and R³ are deprotected to form an oligomer29. Further, (Rp) or (Sp)-20a-d is bonded to a hydroxy group at5′-position of a sugar structure at the end of the oligomer 29. This isrepeated to extend the oligomer chain.

In Scheme 4, though for convenience, all configurations in which aphosphorus atom contained in the intermediate 28 or the oligomer 29 isan asymmetric point is described as an S configuration (Sp isomer), acompound represented by Formula A-1 and a compound represented byFormula A-2 are properly used as a monomer, whereby an H-phosphonatestructure of a S configuration (Sp isomer) and an H-phosphonatestructure of a R configuration (Rp isomer) can be introduced at anyposition.

That is, the intermediate 28 is a compound including a structural unitrepresented by the following Formula T-1 and a structural unitrepresented by the following Formula D-1 or D-2.

In Formula T-1, R² represents a hydrogen atom, a halogen atom, or—OR^(O); R^(O) represents a hydrogen atom, an alkyl group, or aprotecting group of a hydroxy group; Z represents a structurerepresented by any one of Formula B-6 to Formula B-9; and each of * and** represents a binding site with another structure.

In Formula D-1 or Formula D-2, R¹ represents an electron-donating group;n represents an integer of 1 to 5; R² represents a hydrogen atom, ahalogen atom, or —OR^(O); R^(O) represents a hydrogen atom, an alkylgroup, or a protecting group of a hydroxy group; R³ represents ahydrogen atom or a protecting group of a hydroxy group; X represents astructure represented by any one of Formula B-1 to Formula B-5; TfOrepresents a triflate anion; and a black circle (●) represents a bindingsite with another structure.

In Formula B-1 to Formula B-5, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; each of R^(pC),R^(pA), and R^(pG) represents a protecting group that is removed underacidic conditions; R^(pC2) represents a hydrogen atom or an alkyl group;R^(pG2) represents a protecting group; R^(pG3) represents a protectinggroup that is removed under an acidic condition or a hydrogen atom; anda wavy line (

) represents a binding site to another structure.

In Formula B-6 to Formula B-9, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; R^(C), R^(A), andR^(G) represent a hydrogen atom; R^(C2) represents a hydrogen atom or analkyl group; and a wavy line represents a binding site to anotherstructure.

In Formula T-1, R² has the same meaning as R² in Formula A-1 or FormulaA-2, and the same applies to a preferred embodiment thereof.

In Formula T-1, * represents a binding site to another structure, andwhen the synthesis is performed by solid phase synthesis, it ispreferred that * represents a binding site to a support.

In Formula T-1, Z is preferably a structure represented by any one ofFormula B-6 to Formula B-9, and more preferably any one of a thyminestructure, a uracil structure, a cytosine structure, an adeninestructure, or a guanine structure.

In Formula D-1 and Formula D-2, R¹, n, R², R³, and X have the samemeaning as R¹, n, R², R³, and X in Formula A-1 or Formula A-2, and thesame applies to a preferred embodiment thereof.

Formula B-1 to Formula B-5 have the same meaning as Formula B-1 toFormula B-5 in Formula A-1 or Formula A-2 described above, and the sameapplies to a preferred embodiment thereof.

According to a method of producing a boranophosphate oligomer accordingto the present disclosure, both boranophosphate DNA and boranophosphateRNA can be produced, depending on the selection of a polymerizablecompound used in the condensation step.

In the present disclosure, boranophosphate DNA refers to DNA in whichone of non-bridging oxygen atoms in a phosphodiester structure ofnatural DNA is substituted by a borano group (—BH₃).

In the present disclosure, boranophosphate RNA refers to RNA in whichone of non-bridging oxygen atoms in a phosphodiester structure ofnatural RNA is substituted by a borano group (—BH₃).

In any one of the DNA and RNA, it is possible to select thepolymerizable compound according to the embodiment so that a basesequence is complementary to a base sequence of a target nucleic acidand perform synthesis.

In addition, the compound may further include any one or both ofstructural units represented by the following Formula C-1 or FormulaC-2.

The structural unit represented by the following Formula C-1 or FormulaC-2 is a structural unit which is increased by one by one cycle of acondensation cycle described in Scheme 4 described above, and may existin plural.

The total number of the structural units represented by Formula C-1 orFormula C-2 included in the compound is preferably 9 to 100, and morepreferably 11 to 50.

In Formula C-1 or Formula C-2, R² represents a hydrogen atom or —OR^(O);R^(O) represents a hydrogen atom, an alkyl group, or a protecting groupof a hydroxy group; Z represents a structure represented by any one ofFormula B-6 to Formula B-9; and ** and a black circle (●) represent abinding site with another structure.

In Formula B-6 to Formula B-9, R^(T) represents a hydrogen atom, analkyl group, an alkenyl group, or an alkynyl group; R^(C), R^(A), andR^(G) represent a hydrogen atom; R^(C2) represents a hydrogen atom or analkyl group; and a wavy line (●) represents a binding site to anotherstructure.

In Formula C-1 and Formula C-2, Z and R² have the same meaning as Z andR² in Formula T-1, respectively, and the same applies to a preferredembodiment thereof.

When a structure represented by Formula C-1 or Formula C-2 exists inplural, a plurality of Z and R² in Formula C-1 or Formula C-2 may be thesame or different.

Formula B-6 to Formula B-9 have the same meaning as Formula B-6 toFormula B-9 in Formula T-1 described above, and the same applies to apreferred embodiment thereof.

In addition, the compound may further include a structural unit derivedfrom at least one selected from the group consisting of thepolymerizable compound represented by the following Formula E-1 toFormula E-4.

In the condensation step of the present disclosure, at least onepolymerizable compound selected from the group consisting of thepolymerizable compound represented by Formula E-1 to Formula E-4 may befurther used as other polymerizable compounds.

That is, the boranophosphate oligomer produced by the method ofproducing a boranophosphate oligomer according to the present disclosuremay be boranophosphate LNA.

In the present disclosure, LNA refers to an RNA derivative having astructure in which an oxygen atom at 2′-position and a carbon atom at4′-position of a ribose ring are crosslinked via methylene, andboranophosphate LNA refers to LNA in which one of non-bridging oxygenatoms in a phosphodiester structure of LNA is substituted by a boranogroup (—BH₃).

In Formula E-1 to Formula E-4, R¹, n, R³, and X have the same meaning asR¹, n, R³, and X in Formula A-1 or Formula A-2, and the same applies toa preferred embodiment thereof.

In Formula E-3 and Formula E-4, R⁴ represents a protecting group of ahydroxy group, and any of those exemplified as the protecting group of ahydroxy group in R³ described above can be used without limitation.

R⁵ represents a hydrogen atom, a hydroxy group having a protectinggroup, a halogen atom, or an alkoxy group.

When the polymerizable compound represented by Formula E-1 or FormulaE-2 is used in the method of synthesizing of a boranophosphate oligomeraccording to the present disclosure, it is possible to perform synthesisby the same method as the case where the polymerizable compoundrepresented by Formula A-1 or Formula A-2 is used.

In addition, when a polymerizable compound represented by Formula E-3 orFormula E-4 is used in the method of synthesizing a boranophosphateoligomer according to the present disclosure, it is possible to performsynthesis by a known method of synthesizing DNA or RNA, using a knowncondensation reagent.

By using the polymerizable compound represented by Formula E-3 orFormula E-4, it is possible to synthesize a boranophosphate oligomerpartially including a phosphodiester structure.

<Purification Step>

The method of producing a boranophosphate oligomer according to thepresent disclosure may further include a step of producing aboranophosphate oligomer (purification step).

In a purification step, the boranophosphate oligomer is purified by aknown purification method such as reverse phase high performance liquidchromatography (reverse phase HPLC), ion exchange HPLC, columnchromatography, or recrystallization.

In the method of producing a boranophosphate oligomer according to thepresent disclosure is preferably a method of producing a boranophosphateoligomer of a 10-mer to a 100-mer, more preferably a method of producinga boranophosphate oligomer of a 10-mer to a 50-mer, and still morepreferably a method of producing a boranophosphate oligomer of a 12-merto a 50-mer.

According to the method of producing a boranophosphate oligomeraccording to the present disclosure, it is possible to produce aboranophosphate oligomer in which the Sp isomer and the Rp isomerdescribed above are freely combined.

For example, by forming only both ends of the boranophosphate oligomeras an Rp isomer and the other structure as a Sp isomer, it is possibleto produce a boranophosphate oligomer having improved enzyme resistance.

The boranophosphate oligomer obtained by the method of producing aboranophosphate oligomer according to the present disclosure can be usedas an antisense molecule having excellent duplex formation ability to atarget nucleic acid, by designing the boranophosphate oligomer to becomplementary to a base sequence of a target nucleic acid.

For example, when the target nucleic acid corresponds to a partialsequence of a disease-associated gene, the boranophosphate oligomer ispreferably used in a medical use such as an antisense drug having hightranslation inhibition ability.

Furthermore, application to boron neutron capture therapy (BNCT) can bealso considered.

EXAMPLES

Hereinafter, the present disclosure will be described in detail by wayof the Examples, but the present disclosure is not limited thereto.

In addition, in the following description, “%” is based on mass, unlessotherwise specified.

Details of analysis equipment used in the Examples are as follows.

¹H-nuclear magnetic resonance spectrum (¹H-NMR): JNM-LA 400 (400 MHz)

³¹P-nuclear magnetic resonance spectrum (³¹P-NMR): JNM-LA 400 (161.8MHz)

In addition, in ¹H-NMR, tetramethylsilane (TMS) is used as an internalstandard, and in ³¹P-NMR, 85% H₃PO₄ is used as an external standard.

ESI-MS: Varian 910-MS

Details of terms used in the Examples are as follows.

MMTr=4-methoxytrityl

DMTr=4,4′-dimethoxytrityl

TBS=tert-butyldimethylsilyl

TMS=trimethylsilyl

TFA=trifluoroacetic acid

DCA=dichloroacetic acid

MCbz=4-methoxybenzyloxycarbonyl

Tse=trimethylsilylethyl

CDI=1,1′-carbonyldiimidazole

HMDS=hexamethyldisilazane

DEAD=diethylazodicarboxylate

CMPT=N-(cyanomethyl)pyrrolidinium tri fluoromethanesulfonate

DMAc=N,N-dimethylacetamide

BSA=N,O-bis(trimethylsilyl)acetamide

Th (T)=thymine

Cy (C)=cytosine

Ad (A)=adenine

Gu (G)=guanine

Examples and Comparative Examples Synthesis of Polymerizable Compound

[Synthesis of (2S)-5]L-proline (1) (11.51 g, 100 mmol) was dissolved inMeOH (100 mL) and cooled to 0° C. To the solution, SOCl₂ (14.42 mL, 200mmol) was slowly added with a dropping funnel. The reaction mixture wasstirred at room temperature for 3 hours, and the solvent was removedunder reduced pressure to obtain (2S)-2 as a crude product. (2S)-2 wasused for the next step, without further purification.

The crude product (2S)-2 was repeatedly azeotropically dried withtoluene and CHCl₃, and dissolved in CH₂Cl₂ (250 mL), and Et₃N (55.75 mL,400 mmol) and MMTrCl (40.14 g, 130 mmol) were added thereto. Thereaction mixture was stirred at room temperature for 17 hours, and asaturated aqueous NH₄Cl solution-concentrated aqueous NH₃ solution (2:1,v/v) (150 mL) was added thereto. The organic layer was separated andwashed with a saturated aqueous NaHCO₃ solution (3×100 mL), and thecollected washing liquid was extracted with CH₂Cl₂ (100 mL). Thecollected organic layer was dried over anhydrous Na₂SO₄, filtered, andconcentrated under reduced pressure to obtain (2S)-3 as a crude product.(2S)-3 was used for the next step, without further purification.

The crude product (2S)-3 was repeatedly azeotropically dried withpyridine, toluene, and CHCl₃, then dissolved in THF (100 mL). Thesolution was slowly added to a THF solution (100 mL) of LiAlH₄ (4.93 g,130 mmol) at 0° C. with a dropping funnel. The reaction mixture wasstirred at room temperature for 12 hours and cooled to 0° C., and H₂O (5mL), a 15% aqueous NaOH solution (5 mL), and H₂O (15 mL) weresequentially slowly added with a dropping funnel. The reaction mixturewas stirred at room temperature for 30 minutes, anhydrous MgSO₄ wasadded thereto, and the mixture was stirred for another 30 minutes. Thesuspension was filtered through Celite and washed with AcOEt (500 mL).The solution was concentrated under reduced pressure and to the residueCH₂Cl₂ (300 ml) was added. Washing was performed with a saturatedaqueous NaHCO₃ solution (3×100 mL), and the collected washing liquid wasextracted with CH₂Cl₂ (100 mL). The collected organic layer was driedover anhydrous Na₂SO₄, filtered, and concentrated under reduced pressureto give (2S)-4 as a crude product. (2S)-4 was used for the next step,without further purification.

The crude product (2S)-4 was dissolved in CH₂Cl₂ (400 mL), and Et₃N(83.18 mL, 600 mmol) was added thereto. To the solution, a DMSO solution(100 mL) of a pyridine-sulfur trioxide complex (47.75 g, 300 mmol) wasadded at 0° C. The reaction mixture was stirred at room temperature for3 hours, and a saturated aqueous NaHCO₃ solution (100 mL) was addedthereto. The organic layer was separated and washed with saturatedaqueous NaHCO₃ solutions (3×100 mL), and the collected washing liquidwas extracted with CH₂Cl₂ (100 mL). The collected organic layer wasconcentrated under reduced pressure, Et₂O (300 mL) was added to theresidue, and washing was performed with a saturated aqueous NaClsolution (5×100 mL). The collected organic layer was dried overanhydrous Na₂SO₄, filtered, and concentrated under reduced pressure. Theresidue was separated and purified by silica gel column chromatography[neutral silica gel, hexane-AcOEt (6:1, v/v), pyridine 1%] to recover afraction containing (2S)-5. The solvent was removed under reducedpressure to give (2S)-5 as a light yellow foamed material.

¹H NMR (400 MHz, CDCl₃) δ9.84 (s, 1H), 7.55-7.43 (m, 6H), 7.28-7.14 (m,6H), 6.82-6.78 (m, 2H), 3.78 (s, 3H), 3.29-3.23 (m, 1H), 2.93-2.87 (m,1H), 1.64-1.55 (m, 2H), 1.47-1.37 (m, 1H), 1.19-1.10 (m, 1H), 0.90-0.77(m, 1H). FAB-HRMS: Calcd. for [M+Na]⁺; 394.1783. Found; 394.1788

Synthesis of (2R)-5

(2R)-5 was synthesized in the same manner as (2S)-5, using D-proline (1)as a starting material.

¹H NMR (300 MHz, CDCl₃) δ9.83 (s, 1H), 7.56-7.43 (m, 6H), 7.28-7.12 (m,6H), 6.84-6.78 (m, 2H), 3.77 (s, 3H), 3.30-3.21 (m, 1H), 2.94-2.85 (m,1H), 1.65-1.55 (m, 2H), 1.49-1.37 (m, 1H), 1.20-1.08 (m, 1H), 0.90-0.75(m, 1H). FAB-HRMS: Calcd. for [M+Na]⁺; 394.1783. Found; 394.1784.

Synthesis of (αR,2S)-7

(2S)-5 (26.00 g, 70 mmol) was repeatedly azeotropically dried withpyridine, toluene, and CHCl₃, then dissolved in Et₂O (300 mL) and cooledto −78° C. To the solution, a 0.5 M 4-methoxyphenyl magnesiumbromide/THF solution (420 mL, 210 mmol) was slowly added with a droppingfunnel. The reaction mixture was stirred at room temperature for 18hours, and a saturated aqueous NH₄Cl solution-concentrated aqueous NH₃solution (2:1, v/v) (300 mL) was added thereto at 0° C. The suspensionwas filtered through Celite and washed with Et₂O (300 mL). The organiclayer was separated and washed with saturated aqueous NaHCO₃ solutions(3×100 mL), and the collected washing liquid was extracted with Et₂O(100 mL). The collected organic layer was dried over anhydrous Na₂SO₄,filtered, and concentrated under reduced pressure to give (αR,2S)-6 as acrude product. (αR,2S)-6 was used for the next step, without furtherpurification.

To the crude product (αR,2S)-6, a 3% DCA/CH₂Cl₂ solution (300 mL) wasadded. The reaction mixture was stirred at room temperature for 10minutes, H₂O (300 mL) was added thereto, the aqueous layer wasseparated, washed with CH₂Cl₂ (5×100 mL), and the collected washingliquid was extracted with water (100 mL). To the collected aqueouslayer, a 5 M aqueous NaOH solution was added until the pH reached 11.CH₂Cl₂ (300 mL) was added thereto, the organic layer was separated andwashed with a saturated aqueous NaHCO₃ solution (3×100 mL), and thecollected washing liquid was extracted with CH₂Cl₂ (100 mL). Thecollected organic layer was dried over anhydrous Na₂SO₄, filtered, andconcentrated under reduced pressure to give (αRS,2S)-7.

To (αRS,2S)-7 (5.18 g, 25 mmol), trans-cinnamic acid (3.70 g, 25 mmol)was added and recrystallization was performed using EtOH. To theprecipitated crystal, a 2M aqueous KOH solution (100 mL) and CH₂Cl₂ (100mL) was added, and the organic layer was separated. Washing wasperformed with saturated aqueous NaHCO₃ solutions (3×100 mL), and thecollected washing liquid was extracted with CH₂Cl₂ (100 mL). Thecollected organic layer was dried over anhydrous Na₂SO₄, filtered, andconcentrated under reduced pressure to give (αR,2S)-7 as a light yellowoily material.

¹H NMR (400 MHz, CDCl₃) δ7.30-7.27 (m, 2H), 6.89-6.86 (m, 2H), 4.68 (d,J=4.0 Hz, 1H), 3.80 (s, 3H), 3.42-3.37 (m, 1H), 3.05-2.99 (m, 1H),2.96-2.91 (m, 1H), 2.43 (br, 2H), 1.79-1.62 (m, 3H), 1.55-1.47 (m, 1H).FAB-HRMS: Calcd. for [M+H]+; 208.1338. Found; 208.1337.

Synthesis of (αS,2R)-7

(αS,2R)-7 was synthesized in the same manner as (αR,2S)-7, using (2R)-5as a starting material.

¹H NMR (400 MHz, CDCl₃) δ7.30-7.27 (m, 2H), 6.89-6.86 (m, 2H), 4.66 (d,J=4.0 Hz, 1H), 3.80 (s, 3H), 3.40-3.35 (m, 1H), 3.03-2.98 (m, 1H),2.94-2.88 (m, 1H), 2.54 (br, 2H), 1.79-1.61 (m, 3H), 1.55-1.46 (m, 1H).FAB-HRMS: Calcd. for [M+H]⁺; 208.1338. Found; 208.1338.

[Synthesis of 5′-O-(DMTr)thymidine [9a]]

Synthesis was performed according to the method described in theliterature, using thymidine (8) as a starting material. ¹H NMR spectrumwas consistent with the literature value.

Synthesis of 3′,5′-O-bis(TBS)-2′-deoxycytidine [14]

Synthesis was performed according to the method described in theliterature, using 2′-deoxycytidine (13) as a starting material. ¹H NMRspectrum was consistent with the literature value.

Synthesis of 3′, 5′-O-bis(TBS)-N⁴-MCbz-2′-deoxycytidine [15]

3′, 5′-O-bis(TBS)-2′-deoxycytidine (14) (4.55 g, 10 mmol) was repeatedlyazeotropically dried with pyridine, toluene, and CHCl₃, then dissolvedin 1,2-dichloroethane (100 mL), CDI (2.60 g, 16 mmol) was added, andheated to reflux for 20 hours. 4-methoxybenzylalcohol (2.00 mL, 16 mmol)was added thereto, and the mixture was heated to reflux for further 18hours. A saturated aqueous NaHCO₃ solution (100 mL) was added thereto,and the organic layer was separated. Washing was performed withsaturated aqueous NaHCO₃ solutions (3×100 mL), and the collected washingliquid was extracted with CH₂Cl₂ (100 mL). The collected organic layerwas dried over anhydrous Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was separated and purified by silica gelcolumn chromatography [neutral silica gel, hexane-AcOEt (1:1, v/v)] torecover a fraction containing 15. The solvent was removed under reducedpressure to give 15 (4.64 g, 7.49 mmol, 75%) as a colorless foamedmaterial.

¹H NMR (300 MHz, CDCl₃) δ8.38 (d, 1H), 7.46 (br, 1H), 7.34 (d, 2H), 7.18(d, 1H), 6.93 (d, 2H), 6.25 (t, 1H), 5.15 (s, 2H), 4.41 (q, 1H),3.98-3.94 (m, 2H), 3.82-3.76 (m, 4H), 2.56-2.47 (m, 1H), 2.17-2.08 (m,1H), 0.93-0.88 (m, 18H), 0.12-0.05 (m, 12H). FAB-HRMS: Calcd. for[M+H]⁺; 620.3187. Found; 620.3187.

Synthesis of N⁴-MCbz-5′-O-DMTr-2′-deoxycytidine [9b]

3′, 5′-O-bis(TBS)-N⁴-MCbz-2′-deoxycytidine (15) (4.34 g, 7 mmol) wasdissolved in THF (35 mL), 1 M TBAF/THF (35 mL) was added thereto, andstirring was performed at room temperature for 1 hour. A saturatedaqueous NaHCO₃ solution (100 mL) and AcOEt (300 mL) were added, and theorganic layer was separated. Washing was performed with saturatedaqueous NaHCO₃ solutions (3×100 mL), and the collected washing liquidwas extracted with AcOEt (100 mL). The collected organic layer was driedover anhydrous Na₂SO₄, filtered, and concentrated under reducedpressure. To the residue, pyridine (70 mL) and DMTrCl (2.37 g, 7 mmol)were added, and stirred at room temperature for 14 hours. MeOH (30 mL),CHCl₃ (300 mL), and a saturated aqueous NaHCO₃ solution (100 mL) wereadded, and the organic layer was separated. Washing was performed withsaturated aqueous NaHCO₃ solutions (3×100 mL), and the collected washingliquid was extracted with CHCl₃ (100 mL). The collected organic layerwas dried over anhydrous Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was separated and purified by silica gelcolumn chromatography [neutral silica gel, CH₂Cl₂-MeOH-pyridine(99:0.5:0.5 to 94.5:5:0.5, v/v)] to recover a fraction containing 9b.The solvent was removed under reduced pressure to give 9b (3.47 g, 5mmol, 71%) as a colorless foamed material.

¹H NMR (300 MHz, CDCl₃) δ8.25 (d, 1H), 7.44-7.39 (m, 3H), 7.34-7.22 (m,9H), 7.02 (d, 1H), 6.92-6.84 (m, 6H), 6.25 (t, 1H), 5.13 (s, 2H), 4.47(br, 1H), 4.09 (q, 1H), 3.80 (s, 9H), 3.55-3.39 (m, 2H), 2.71-2.62 (m,1H), 2.30-2.22 (m, 1H). FAB-HRMS: Calcd. for [M+H]+; 694.2765. Found;694.2763.

Synthesis of 3′,5′-O-bis(TBS)-2′-deoxyadenosine [11]

Synthesis was performed according to the method described in theliterature, using 2′-deoxyadenosine (10) as a starting material. ¹H NMRspectrum was consistent with the literature value.

Synthesis of 3′,5′-O-bis(TBS)-N⁶-MCbz-2′-deoxyadenosine [12]

3′, 5′-O-bis(TBS)-2′-deoxyadenosine (11) (7.19 g, 15 mmol) wasrepeatedly azeotropically dried with pyridine, toluene, and CHCl₃ toform a 1,2-dichloroethane solution (150 mL), CDI (3.89 g, 24 mmol) wasadded, and heated to reflux for 17 hours. 4-methoxybenzylalcohol (3.00mL, 24 mmol) was added thereto, and heated to reflux for further 20hours. A saturated aqueous NaHCO₃ solution (100 mL) was added thereto,and the organic layer was separated. Washing was performed withsaturated aqueous NaHCO₃ solutions (3×100 mL), and the collected washingliquid was extracted with CH₂Cl₂ (100 mL). The collected organic layerwas dried over anhydrous Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was separated and purified by silica gelcolumn chromatography [neutral silica gel, hexane-AcOEt (2:1, v/v)] torecover a fraction containing 12. The solvent was removed under reducedpressure to give 12 (7.26 g, 11 mmol, 75%) as a colorless foamedmaterial.

¹H NMR (400 MHz, CDCl₃) δ8.75 (s, 1H), 8.41 (s, 1H), 8.26 (s, 1H), 8.38(d, 2H), 6.90 (d, 2H), 6.49 (t, 1H), 5.23 (s, 2H), 4.63-4.59 (m, 1H),4.04 (q, 1H), 3.89-3.75 (m, 5H), 2.67-2.61 (m, 1H), 2.48-2.42 (m, 1H),0.92-0.87 (m, 18H), 0.10-0.04 (m, 12H). FAB-HRMS: Calcd. for [M+H]+;644.3300. Found; 644.3298.

Synthesis of N⁶-MCbz-5′-O-DMTr-2′-deoxyadenosine [9c]

3′, 5′-O-bis(TBS)-N⁶-MCbz-2′-deoxyadenosine (12) (7.26 g, 11 mmol) wasdissolved into THF (55 mL), 1 M TBAF/THF (55 mL) was added thereto, andstirring was performed at room temperature for 1 hour. A saturatedaqueous NaHCO₃ solution (100 mL) and AcOEt (300 mL) were added, and theorganic layer was separated. Washing was performed with saturatedaqueous NaHCO₃ solutions (3×100 mL), and the collected washing liquidwas extracted with AcOEt (100 mL). The collected organic layer was driedover anhydrous Na₂SO₄, filtered, and concentrated under reducedpressure. To the residue, pyridine (110 mL) and DMTrCl (4.48 g, 13.2mmol) were added, and stirred at room temperature for 18 hours. MeOH (50mL), CHCl₃ (300 mL), and a saturated aqueous NaHCO₃ solution (100 mL)were added, and the organic layer was separated. Washing was performedwith a saturated aqueous NaHCO₃ solution (3×100 mL), and the collectedwashing liquid was extracted with CHCl₃ (100 mL). The collected organiclayer was dried over anhydrous Na₂SO₄, filtered, and concentrated underreduced pressure. The residue was separated and purified by silica gelcolumn chromatography [neutral silica gel, CH₂Cl₂-MeOH-pyridine(98:1.5:0.5 to 96.5:3:0.5, v/v)] to recover a fraction containing 9c.The solvent was removed under reduced pressure to give 9c (5.08 g, 7mmol, 64%) as a colorless foamed material.

¹H NMR (300 MHz, CDCl₃) δ8.68 (s, 1H), 8.16 (br, 1H), 8.06 (s, 1H),7.40-7.36 (m, 2H), 7.31-7.16 (m, 9H), 6.91-6.77 (m, 6H), 6.46 (t, 1H),5.23 (s, 2H), 4.70 (br, 1H), 4.16 (q, 1H), 3.77 (s, 9H), 3.41-3.39 (m,2H), 2.91-2.82 (m, 1H), 2.59-2.51 (m, 1H), 1.65 (br, 1H). FAB-HRMS:Calcd. for [M+H]+; 718.2877. Found; 718.2880.

Synthesis of O⁶-Tse-5′-O-DMTr-2′-deoxyguanosine [9d]

Synthesis was performed according to the method described in theliterature, using 2′-deoxyguanosine (1) as a starting material. ¹H NMRspectrum was consistent with the literature value.

Synthesis of 3′,5′-bis-O-benzoyl-N²-MCbz-deoxyguanosine [6]

3′,5′-bis-O-benzoyldeoxyguanosine (4) (0.52 g, 1.09 mmol) was dissolvedin THF (13.0 mL), DIPEA (0.95 mL, 5.5 mmol) and TMSCl (0.15 mL, 1.0mmol) were added thereto, and stirring was performed at room temperaturefor 1 hour. Triphosgene (0.1 g, 0.35 mmol) was added and stirred at 0°C. for 1 hour. 4-methoxybenzylalcohol (0.17 g, 1.2 mmol) was added atroom temperature, and heated to reflux overnight. Washing was performedwith saturated saline solutions (3×10 mL), and the collected washingliquid was extracted with CH₂Cl₂ (5 mL). The collected organic layer wasdried over anhydrous Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was separated and purified by silica columnchromatography [neutral silica gel, CH₂Cl₂-MeOH-pyridine (99:0.5:0.5 to94.5:5:0.5, v/v)] to recover a fraction containing 6. The solvent wasremoved under reduced pressure to give 6 (0.09 g, 0.40 mmol, 37%) as ayellow foamed material.

¹H NMR (300 MHz, CDCl₃) δ 11.31 (s, 1H), 8.35 (s, 1H), 8.06-8.04 (d,J=7.5 Hz, 2H), 7.96-7.93 (d, J=7.2 Hz, 2H), 7.72 (s, 1H), 7.64-7.59 (m,1H), 7.55-7.45 (m, 9H), 7.39-7.34 (m, 4H), 6.94-6.92 (m, 2H), 6.30-6.26(t, J=7.2, 6.6 Hz, 1H), 5.80-5.78 (m, 1H), 5.23 (s, 2H), 4.94-4.90 (m,1H), 4.75-4.69 (m, 1H), 4.69-4.67 (m, 1H), 3.83 (s, 1H), 3.17-3.07 (m,1H), 2.70-2.65 (m, 1H).

Synthesis of 2-chloro-1,3,2-oxazaphospholidine [(4S,5R)-18]

(αR,2S)-7 (1.07 g, 5.16 mmol) was repeatedly azeotropically dried withtoluene, then dissolved in toluene (3 mL), and N-methylmorpholine (1.13mL, 10.32 mmol) was added thereto. The mixed solution was slowly addedto a solution of phosphorus trichloride (0.45 mL, 5.16 mmol) in toluene(2.5 mL) at 0° C. with a syringe. The reaction mixture was stirred atroom temperature for 2 hours, and the resulting salt was filtered off at−78° C. under an Ar atmosphere and concentrated under reduced pressureunder an Ar atmosphere to give 2-chloro-1,3,2-oxazaphospholidine(4S,5R)-18 (1.28 g, 4.71 mmol). Light yellow oil. (4S,5R)-18 was usedfor the reaction, without further purification.

Synthesis of [(4R,5S)-18]

Synthesis was performed in the same manner as (4S,5R)-18, using(αS,2R)-7 as a starting material.

Synthesis of Oxazaphospholidine Monomer [(Rp)-20a]

5′-O-(DMTr)thymidine (9a) (0.86 g, 1.58 mmol) was repeatedlyazeotropically dried with pyridine, toluene and THF, then dissolved inTHF (8 mL), and Et₃N (1.52 mL, 11 mmol) was added thereto. The mixedsolution was cooled to −78° C. and a solution of 0.5 M (4S,5R)-18 in THF(9.5 mL, 4.75 mmol) was slowly added thereto with a syringe. Thereaction solution was stirred at room temperature for 2 hours, and CHCl₃(300 mL) and a saturated aqueous NaHCO₃ solution (100 mL) was addedthereto. The organic layer was separated and washed with saturatedaqueous NaHCO₃ solutions (2×100 mL), and the collected washing liquidwas extracted with CHCl₃ (100 mL). The collected organic phase was driedover anhydrous Na₂SO₄, filtered, and concentrated under reducedpressure. The residue was separated and purified by silica gel columnchromatography [NH-silica gel, toluene-AcOEt (7:3, v/v), Et₃N 0.1%], afraction containing (Rp)-20a was collected, and the solvent was removedunder reduced pressure to give (Rp)-20a (0.53 g, 0.68 mmol, 43%) as acolorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ7.60 (s, 1H), 7.41-7.22 (m, 11H), 6.89-6.79 (m,6H), 6.43 (t, 1H), 5.68 (d, 1H), 4.94-4.89 (m, 1H), 4.13 (q, 1H),3.80-3.77 (m, 10H), 3.60-3.53 (m, 1H), 3.49-3.36 (m, 2H), 3.20-3.13 (m,1H), 2.60-2.55 (m, 1H), 2.40-2.33 (m, 1H), 1.66-1.58 (m, 2H), 1.42 (s,3H), 1.21-1.14 (m, 1H), 1.00-0.91 (m, 1H). ³¹P NMR (161 MHz, CDCl₃) δ155.65. FAB-HRMS: Calcd. for [M+Na]⁺; 802.2869. Found; 802.2866.

The crude products of (Rp)-20b-d and (Sp)-20a-d were all obtained by thesame method as described above. Only the conditions for silica gelcolumn chromatography are shown for these compounds.

Synthesis of Oxazaphospholidine Monomer [(Rp)-20b]

The crude product of (Rp)-20b was obtained from 9b (1.02 g, 1.47 mmol)and (4S,5R)-18 (0.80 g, 2.94 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (7:3, v/v), Et₃N 0.1%] to give (Rp)-20b(0.65 g, 0.70 mmol, 47%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ8.25 (d, 1H), 7.39-7.13 (m, 13H), 6.91-6.79 (m,8H), 6.26 (t, 1H), 5.68 (d, 1H), 5.13 (s, 2H), 4.87-4.81 (m, 1H), 4.16(q, 1H), 3.83-3.76 (m, 14H), 3.60-3.52 (m, 1H), 3.47 (d, 2H), 3.22-3.13(m, 1H), 2.82-2.75 (m, 1H), 2.38-2.32 (m, 1H), 1.67-1.57 (m, 2H),1.22-1.15 (m, 1H), 1.01-0.94 (m, 1H). ³¹P NMR (161 MHz, CDCl₃) δ 156.72.FAB-HRMS: Calcd. for [M+H]+; 929.3527. Found; 929.3528.

Synthesis of Oxazaphospholidine Monomer [(Rp)-20c]

The crude product of (Rp)-20c was obtained from 9c (1.05 g, 1.47 mmol)and (4S,5R)-18 (0.80 g, 2.94 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (8:2, v/v), Et₃N 0.1%] to give (Rp)-20c(0.62 g, 0.65 mmol, 44%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ8.67 (s, 1H), 8.30 (br, 1H), 8.06 (s, 1H),7.38-7.35 (m, 4H), 7.29-7.14 (m, 9H), 6.91-6.86 (m, 4H), 6.75-6.70 (m,4H), 6.47 (t, 1H), 5.77 (d, 1H), 5.22 (s, 2H), 5.09-5.03 (m, 1H), 4.29(q, 1H), 3.88-3.84 (m, 1H), 3.81 (s, 6H), 3.74 (s, 6H), 3.62-3.54 (m,1H), 3.41-3.33 (m, 2H), 3.20-3.11 (m, 1H), 2.99-2.92 (m, 1H), 2.71-2.65(m, 1H), 1.68-1.59 (m, 2H), 1.26-1.16 (m, 1H), 1.03-0.94 (m, 1H). ³¹PNMR (161 MHz, CDCl₃) δ 154.97. FAB-HRMS: Calcd. for [M+Na]⁺; 975.3458.Found; 975.3459.

Synthesis of Oxazaphospholidine Monomer [(Rp)-20d]

The crude product of (Rp)-20d was obtained from 9d (0.67 g, 1.00 mmol)and (4S,5R)-18 (1.07 g, 3.95 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (9:1, v/v), Et₃N 0.1%] to give (Rp)-20d(0.34 g, 0.38 mmol, 38%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ7.69 (s, 1H), 7.43-7.13 (m, 11H), 6.92-6.74 (m,6H), 6.33 (t, 1H), 5.75 (d, 1H), 5.04 (m, 1H), 4.65-4.53 (m, 4H), 4.26(q, 1H), 3.92-3.74 (m, 10H), 3.64-3.53 (m, 1H), 3.41-3.30 (m, 2H),3.20-3.13 (m, 1H), 2.57-2.55 (m, 1H), 2.24-2.19 (m, 1H), 1.68-1.55 (m,2H), 1.26-1.12 (m, 3H), 1.03-0.96 (m, 1H), 0.08 (s, 9H). ³¹P NMR (161MHz, CDCl₃) δ 155.04. FAB-HRMS: Calcd. for [M+H]⁺; 905.3823. Found;905.3826.

[Oxazaphospholidine Monomer [(Sp)-20a]]

The crude product of (Sp)-20a was obtained from 9a (0.85 g, 1.57 mmol)and (4R,5S)-18 (1.28 g, 4.71 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (7:3, v/v), Et₃N 0.1%] to give (Sp)-20a(0.82 g, 1.05 mmol, 67%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ8.02 (br, 1H), 7.64 (s, 1H), 7.42-7.16 (m,11H), 6.90-6.82 (m, 6H), 6.41 (t, 1H), 5.63 (d, 1H), 4.94-4.89 (m, 1H),4.18 (q, 1H), 3.86-3.76 (m, 10H), 3.56-3.48 (m, 1H), 3.39-3.34 (m, 2H),3.20-3.13 (m, 1H), 2.50-2.43 (m, 1H), 2.39-2.31 (m, 1H), 1.64-1.59 (m,2H), 1.40 (s, 3H), 1.25-1.19 (m, 1H), 1.06-0.90 (m, 1H). ³¹P NMR (161MHz, CDCl₃) δ 156.12. FAB-HRMS: Calcd. for [M+Na]⁺; 802.2869. Found;802.2874.

Synthesis of oxazaphospholidine monomer [(Sp)-20b]

The crude product of (Sp)-20b was obtained from 9b (1.01 g, 1.46 mmol)and (4R,5S)-18 (1.00 g, 3.67 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (7:3, v/v), Et₃N 0.1%] to give (Sp)-20b(0.55 g, 0.59 mmol, 40%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ8.36 (d, 1H), 7.43-7.16 (m, 13H), 6.94-6.84 (m,8H), 6.24 (t, 1H), 5.68 (d, 1H), 5.13 (s, 2H), 4.90-4.83 (m, 1H), 4.18(q, 1H), 3.87-3.76 (m, 14H), 3.57-3.44 (m, 3H), 3.21-3.13 (m, 1H),2.69-2.63 (m, 1H), 2.41-2.32 (m, 1H), 1.69-1.60 (m, 2H), 1.25-1.17 (m,1H), 1.04-0.95 (m, 1H). ³¹P NMR (161 MHz, CDCl₃) δ 155.97. FAB-HRMS:Calcd. for [M+Na]⁺; 951.3346. Found; 951.3349.

Synthesis of Oxazaphospholidine Monomer [(Sp)-20c]

The crude product of (Sp)-20c was obtained from 9c (1.05 g, 1.46 mmol)and (4R,5S)-18 (1.00 g, 3.67 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (8:2, v/v), Et₃N 0.1%] to give (Sp)-20c(0.67 g, 0.70 mmol, 48%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ8.67 (s, 1H), 8.29 (br, 1H), 8.11 (s, 1H),7.41-7.35 (m, 4H), 7.30-7.12 (m, 9H), 6.91-6.74 (m, 8H), 6.46 (t, 1H),5.72 (d, 1H), 5.22 (s, 2H), 5.06-5.00 (m, 1H), 4.34 (q, 1H), 3.91-3.85(m, 1H), 3.80 (s, 6H), 3.76 (s, 6H), 3.62-3.52 (m, 1H), 3.48-3.34 (m,2H), 3.22-3.13 (m, 1H), 2.94-2.88 (m, 1H), 2.63-2.58 (m, 1H), 1.69-1.58(m, 2H), 1.26-1.19 (m, 1H), 1.06-0.98 (m, 1H). ³¹P NMR (161 MHz, CDCl₃)δ 155.36. FAB-HRMS: Calcd. for [M+H]⁺; 953.3639. Found; 953.3643.

Synthesis of Oxazaphospholidine Monomer [(Sp)-20d]

The crude product of (Sp)-20d was obtained from 9d (0.67 g, 1.00 mmol)and (4R,5S)-18 (1.07 g, 3.95 mmol), by the same method as (Rp)-20a.Purification was performed by silica gel column chromatography[NH-silica gel, toluene-AcOEt (9:1, v/v), Et₃N 0.1%] to give (Sp)-20d(0.34 g, 0.38 mmol, 38%) as a colorless foamed material.

¹H NMR (400 MHz, CDCl₃) δ7.73 (s, 1H), 7.44-7.13 (m, 11H), 6.88-6.78 (m,6H), 6.30 (t, 1H), 5.71 (d, 1H), 5.01 (m, 1H), 4.61-4.53 (m, 4H), 4.30(q, 1H), 3.90-3.77 (m, 10H), 3.62-3.52 (m, 1H), 3.46-3.42 (m, 1H),3.33-3.30 (m, 1H), 3.22-3.13 (m, 1H), 2.52-2.48 (m, 1H), 2.25-2.20 (m,1H), 1.66-1.59 (m, 2H), 1.26-1.19 (m, 3H), 1.07-0.98 (m, 1H), 0.08 (s,9H). ³¹P NMR (161 MHz, CDCl₃) δ 155.36. FAB-HRMS: Calcd. for [M+H]⁺;905.3823. Found; 905.3825.

9a to 9d (base protected by a protecting group), Compound 18 used forsynthesis of each monomer, a yield of each monomer, and a mass ratio ofan Rp isomer and a Sp isomer contained in the obtained monomer aredescribed in Table 1.

In Table 1, Th represents thymine, Cy^(MCbz) represents cytosine ofwhich the amino group is protected by an MCbz group, Ad^(MCbz)represents adenine of which the amino group is protected by an MCbzgroup, and Gu^(Tse) represents guanine of which the amino group isprotected by a trimethylsilyl group, respectively.

TABLE 1 9a to 9d 20 Used Included Yield Entry compound base 18 (%)Rp:Sp^(b) 1 9a Th (4S, 5R) 43 >99:1 2 9b Cy^(MCbz) (4S, 5R) 47 >99:1 39c Ad^(MCbz) (4S, 5R) 44 >99:1 4 9d Gu^(Tse) (4S, 5R) 37 >99:1 5 9a Th(4R, 5S) 67  >1:99 6 9b Cy^(MCbz) (4R, 5S) 40  >1:99 7 9c Ad^(MCbz) (4R,5S) 48  >1:99 8 9d Gu^(Tse) (4R, 5S) 38  >1:99 ^(a) In entries 4 to 8, aprocessing condition by Et₃N described above was at −78° C. ^(b31)P NMRwas used for measurement.

Synthesis 1 of Boranophosphate DNA

Manual solid phase synthesis of boranophosphate DNA (PB-DNA)(24a-d,25,26) was performed using a controlled-pore glass (CPG) as asolid support and a glass filter (10 mm×50 mm) having a cock at thebottom as a reaction vessel.

First, 5′-O-(DMTr)thymidine (27) supported on CPG via succinyl linkerwas treated with 1% TFA/CH₂Cl₂ (4×5 s) to remove a 5′-O-DMTr group, andthe following steps (i) to (v) were performed to synthesizeH-phosphonate DNA (23).

-   -   (i) washing (CH₂Cl₂, CH₃CN)    -   (ii) coupling (0.2M monomer 20a-d and 1.0M CMPT(21) in CH₃CN; 5        min),    -   (iii) washing (CH₃CN, CH₂Cl₂)    -   (iv) 1% TFA/CH₂Cl₂-Et₃SiH (1:1,v/v)(4×1 min)    -   (v) washing (CH₂Cl₂, CH₃CN)

Subsequently, DMAc (0.8 mL), BSA (0.1 mL), and BH₃.SMe2 (0.1 mL) wereadded to the synthesized 23 at room temperature. After 15 minutes, thereaction solution was removed and CPG was washed with DMAc and CH₃CN.CPG was treated with concentrated aqueous NH₃ solution-EtOH(3:1, v/v) at25° C. for 3 hours or 55° C. for 12 hours, CPG was filtered off, and thefiltrate was concentrated under reduced pressure. The residue wasanalyzed and identified by RP-HPLC and ESI-MS.

A sequence of the obtained boranophosphate DNA (PB-DNA), reactionconditions for release el the oligomer from a solid support (temperatureand retention time under a condition of conc. NH₃-EtOH (3:1, v/v)), ayield, and a stereochemical purity of a dimer are listed in Table 2,respectively. In addition, in Table 2, description of Rp or Sp indicateswhether the absolute configuration of a boranophosphate structure in theoligomer is Sp or Rp. The description of all-(Rp) indicates that theabsolute configuration of a boranophosphate structure in the oligomer isall Rp, and the description of all-(Sp) indicates that the absoluteconfiguration of a boranophosphate structure in the oligomer is all Sp,respectively.

TABLE 2 Conditions for release oligomer from solid Yield StereochemicalEntry Sequence of PB-DNA^(a) support (%)^(b) purity^(b) 1 (Rp)-24a(Rp)-T_(B)T 25° C., 3 h  91  98:2 2 (Rp)-24b (Rp)-dC_(B)T 25° C., 3 h 91 >99:1 3 (Rp)-24c (Rp)-dA_(B)T 25° C., 3 h  — >99:1 4 (Rp)-24c(Rp)-dA_(B)T 55° C., 12 h 88 >99:1 5 (Rp)-24d (Rp)-dG_(B)T 55° C., 12 h77 >99:1 6 (Sp)-24a (Sp)-T_(B)T 25° C., 3 h  88 >99:1 7 (Sp)-24b(Sp)-dC_(B)T 25° C., 3 h  93  98:2 8 (Sp)-24c (Sp)-dA_(B)T 25° C., 3 h — >99:1 9 (Sp)-24c (Sp)-dA_(B)T 55° C., 12 h 87 >99:1 10 (Sp)-24d(Sp)-dG_(B)T 55° C., 12 h 77  97:3 11 25 all-(Rp)-d(C_(B)A_(B)G_(B)T)55° C., 12 h  14 ^(c) — 12 26 all-(Sp)-d(C_(B)A_(B)G_(B)T) 55° C., 12 h 23 ^(c) — ^(a)“B” represents being bonded by a boranophosphatestructure. ^(b)Calculated by reverse phase HPLC. The HPLC charts areshown in FIGS. 1 to 7. ^(c) Isolated yield

FIG. 1 is HPLC charts showing results of reverse phase HPLC of (A) asynthesis reaction solution (crude) of (Rp)-T_(B)T [(Rp)-24a] and (B) asynthesis reaction solution (crude) of (Sp)-T_(B)T [(Sp)-24a].

The measurement conditions of the reverse phase HPLC were as follows.

Gradient cycle: After a linear gradient of acetonitrile from 0% to 10%for 30 minutes in a 0.1 M triethylammonium buffer solution (pH 7.0),acetonitrile was held at 10% for 30 minutes.

Measurement temperature: 30° C.

Flow rate: 0.5 mL/min

Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm) (Waters)

FIG. 2 is HPLC charts showing results of reverse phase HPLC of (C) asynthesis reaction solution (crude) of (Rp)-dC_(B)T [(Rp)-24b] and (D) asynthesis reaction solution (crude) of (Sp)-dC_(B)T [(Sp)-24b].

The measurement conditions of the reverse phase HPLC were as follows.

Gradient cycle: After a linear gradient of acetonitrile from 0% to 10%for 30 minutes in a 0.1 M triethylammonium buffer solution (pH 7.0),acetonitrile was held at 10% for 20 minutes.

-   -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

FIG. 3 is HPLC charts showing results of reverse phase HPLC of (E) asynthesis reaction solution (crude) of (Rp)-dA_(B)T [(Rp)-24c] and (D) asynthesis reaction solution (crude) of (Sp)-dA_(B)T [(Sp)-24c].

The measurement conditions of the reverse phase HPLC were as follows.

Gradient cycle: A linear gradient of acetonitrile from 0% to 30% for 60minutes in a 0.1 M triethylammonium buffer solution (pH 7.0).

-   -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

FIG. 4 is HPLC charts showing results of reverse phase HPLC of (G) asynthesis reaction solution (crude) of (Rp)-dA_(B)T [(Rp)-24c] and (H) asynthesis reaction solution (crude) of (Sp)-dA_(B)T [(Sp)-24c].

The measurement conditions of the reverse phase HPLC were as follows.

-   -   Gradient cycle: A linear gradient of acetonitrile from 0% to 30%        for 60 minutes in a 0.1 M triethylammonium buffer solution (pH        7.0).    -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

FIG. 5 is HPLC charts showing results of reverse phase HPLC of (1) asynthesis reaction solution (crude) of (Rp)-dG_(B)T [(Rp)-24d] and (J) asynthesis reaction solution (crude) of (Sp)-dG_(B)T [(Sp)-24d].

The measurement conditions of the reverse phase HPLC were as follows.

-   -   Gradient cycle: A linear gradient of acetonitrile from 0% to 30%        for 60 minutes in a 0.1 M triethylammonium buffer solution (pH        7.0).    -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

FIG. 6 is HPLC charts showing results of reverse phase HPLC of (K) asynthesis reaction solution (crude) of all-(Rp)-d (C_(B)A_(B)G_(B)T)[25] and (L) a synthesis reaction solution (crude) of all-(Sp)-d(C_(B)A_(B)G_(B)T) [26].

The measurement conditions of the reverse phase HPLC were as follows.

-   -   Gradient cycle: A linear gradient of acetonitrile from 0% to 20%        for 60 minutes in a 0.1 M triethylammonium buffer solution (pH        7.0).    -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

FIG. 7 is HPLC charts showing results of reverse phase HPLC of (K) apurified product of all-(Rp)-d (C_(B)A_(B)G_(B)T) [25] and (L) apurified product of all-(Sp)-d (C_(B)A_(B)G_(B)T) [26].

The measurement conditions of the reverse phase HPLC were as follows.

-   -   Gradient cycle: A linear gradient of acetonitrile from 0% to 20%        for 60 minutes in a 0.1 M triethylammonium buffer solution (pH        7.0).    -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

The sequence of the obtained boranophosphate DNA (PB-DNA), the chemicalformula [—H⁺], the theoretical value of a molecular weight (MS), and themeasured value by ESI-MS are shown in Table 3, respectively. Inaddition, in Table 3, description of Rp or Sp indicates whether theabsolute configuration of a boranophosphate structure in the oligomer isSp or Rp. The description of all-(Rp) indicates that the absoluteconfiguration of a boranophosphate structure in the oligomer is all Rp,and the description of all-(Sp) indicates that the absoluteconfiguration of a boranophosphate structure in the oligomer is all Sp,respectively.

TABLE 3 Chemical Formula Theoretical Measured PB-DNA ^(a) [−H⁺] valuevalue (Rp)-24a (Rp)-T_(B)T C₂₀H₂₉BN₄O₁₁P⁻ 542.1705 542.1695 (Rp)-24b(Rp)-dC_(B)T C₁₉H₂₈BN₅O₁₀P⁻ 527.1709 527.1708 (Rp)-24c (Rp)-dA_(B)TC₂₀H₂₈BN₇O₉P⁻ 551.1821 551.1826 (Rp)-24d (Rp)-dG_(B)T C₂₀H₂₈BN₇O₁₀P⁻567.1770 567.1761 (Sp)-24a (Sp)-T_(B)T C₂₀H₂₉BN₄O₁₁P⁻ 542.1705 542.1700(Sp)-24b (Sp)-dC_(B)T C₁₉H₂₈BN₅O₁₀P⁻ 527.1709 527.1710 (Sp)-24c(Sp)-dA_(B)T C₂₀H₂₈BN₇O₉P⁻ 551.1821 551.1821 (Sp)-24d (Sp)-dG_(B)TC₂₀H₂₈BN₇O₁₀P⁻ 567.1770 567.1763 25 all-(Rp)-d(C_(B)A_(B)G_(B)T)C₃₉H₅₇B₃N₁₅O₁₉P₃ ⁻ 1166.3549 1166.3547 26 all-(Sp)-d(C_(B)A_(B)G_(B)T)C₃₉H₅₇B₃N₁₅O₁₉P₃ ⁻ 1166.3549 1166.3542 ^(a) “B” represents being bondedby a boranophosphate structure.

Synthesis 2 of Boranophosphate DNA

According to the following scheme, boranophosphate DNA (PB-DNA) [27] wassynthesized. The sequence was all-(Sp)-d(G_(B)T_(B)(A_(B)C_(B)T_(B))₃T).A controlled-pore glass (CPG) as a solid support and a glass filter (10mm×50 mm) having a cock at the bottom of a reaction vessel were used.The isolated yield was 1.5%.

Other detailed reaction conditions are shown in the following Table 4.

TABLE 4 step manipulation reagents and solvents time 1 detritylation 1%TFA in DCM 15 s 2 wash (1) DCM (2) CH₃CN — 3 drying — 5 min 4condensation monomer units (0.2M), CMPT (1.0M)/ 5 min CH₃CN 5 wash CH₃CN— 6 drying — 5 min 7 wash (1) DCM (2) CH₃CN — 8 detritylation anddeprotection 1% TFA in DCM-Et₃SiH (1:1, v/v) 5 min repeat steps 2-8 inorder to synthesize the objective sequence 9 wash (1) DCM (2) CH₃CN — 10boronation BH₃•SMe₂-BSA-DMAc (1:1:8, v/v/v) 15 min 11 wash (1) DMAc (2)CH₃CN — 12 release the oligomer from the CPG sat. NH₃aq-EtOH (3:1, v/v,50° C.) 12 h

In Table 4, monomer units represent Compound 20a-d.

FIG. 8 is HPLC charts showing results of reverse phase HPLC of (O) asynthesis reaction solution (crude) ofall-(Sp)-d(G_(B)T_(B)(A_(B)C_(B)T_(B))₃T) [27] and (P) a purifiedproduct of all-(Sp)-d(G_(B)T_(B)(A_(B)C_(B)T_(B))₃T) [27].

The measurement conditions of the reverse phase HPLC were as follows.

Gradient cycle: A linear gradient of acetonitrile from 0% to 40% for 60minutes in a 0.1 M triethylammonium buffer solution (pH 7.0).

-   -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

Synthesis 3 of Boranophosphate DNA (Comparative Example)

According to the following scheme, boranophosphate DNA (PB-DNA) [28, 29]was synthesized. The sequence wasall-(Sp)-d(C_(B)A_(B)G_(B)T_(B))₂(CBABGB)T [28] orall-(Rp)-d(C_(B)A_(B)G_(B)T_(B))₂(CBABGB)T [29]. A controlled-pore glass(CPG) as a solid support and a glass filter (10 mm×50 mm) having a cockat the bottom of reaction vessel were used.

Other detailed reaction conditions are shown in the following Table 5.

TABLE 5 step manipulation reagents and solvents time 1 detritylation 1%TFA in DCM 15 s 2 wash (1) DCM (2) CH₃CN — 3 drying — 10 min 4condensation monomer units (0.2M), CMDMT 5 min (0.5M)/CH₃CN-NMP (4:1,v/v) 5 wash CH₃CN — 6 drying — 5 min 7 capping capping amidite (0.5M),CMPT 5 min (1.0M)/ CH₃CN 8 wash (1) DCM (2) CH₃CN — 9 detritylation anddeprotection 1% TFA in DCM-Et₃SiH (1:1, v/v) 15 s repeat steps 2-9 inorder to synthesize the objective sequence 10 wash (1) DCM (2) CH₃CN —11 boronation BH₃•SMe₂-BSA-DMAc (1:1:8, v/v/v) 15 min 12 wash (1) DMAc(2) CH₃CN (3) CH₂OH — 13 release the oligomer from the HCP sat. NH₃ inCH₂OH (50° C., 0.1 mM) 12 h resin

FIG. 9 is HPLC charts showing results of reverse phase HPLC of (Q) asynthesis reaction solution (crude) ofall-(Sp)-d(C_(B)A_(B)G_(B)T_(B))₂(CBABGB)T[28] and (R) a synthesisreaction solution (crude) of all-(Rp)-d(C_(B)A_(B)G_(B)T_(B))₂(CBABGB)T[29].

The measurement conditions of the reverse phase HPLC were as follows.

Gradient cycle: A linear gradient of acetonitrile from 0% to 40% for 60minutes in a 0.1 M triethylammonium buffer solution (pH 7.0).

-   -   Measurement temperature: 30° C.    -   Flow rate: 0.5 mL/min    -   Column: μBondasphere 5 μm C18 column (100 Å, 3.9 mm×150 mm)        (Waters)

As can be seen from FIG. 9 , according to the Comparative Example, itwas impossible to synthesize boranophosphate DNA.

1. A polymerizable compound represented by any one selected from thefollowing Formula E-1 or E-2:

wherein, in Formula E-1 and E-2, R¹ represents an alkoxy group,—NR^(N)2, a hydroxy group, an aryl group, or an alkyl group, whereinR^(N) each independently represents a hydrogen atom or an alkyl grouphaving 1 to 10 carbon atoms; n represents an integer from 1 to 5; R³represents a hydrogen atom, an acetyl group, a phenoxyacetyl group, apivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoylgroup, a triphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, atrimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethylgroup, or a cyanoethoxymethyl group; and X represents a structurerepresented by any one of Formula B-1 to Formula B-5, and wherein, inFormula B-1 to Formula B-5, R^(T) represents a hydrogen atom, an alkylgroup, an alkenyl group, or an alkynyl group; each of R^(pC), R^(pA),and R^(pG) represents a tert-butoxycarbonyl group, a benzyloxycarbonylgroup, a 4,4′-trimethoxytrityl (TMTr) group, a 4,4′-dimethoxytrityl(DMTr) group, a 4-methoxytrityl (MMTr) group, or4-methoxybenzyloxycarbonyl (MCBz) group; R^(pC2) represents a hydrogenatom; R^(pG2) represents an acetyl group, a phenoxyacetyl group, apivaloyl group, a benzyl group, a 4-methoxybenzyl group, a benzoylgroup, a triphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, atrimethylsilyl group, a trimethylsilylethyl group, a cyanomethoxymethylgroup, a 2-(cyanoethoxy)ethyl group, or a cyanoethoxymethyl group;R^(pG3) represents a tert-butoxycarbonyl group, a benzyloxycarbonylgroup, a 4,4′-trimethoxytrityl (TMTr) group, a 4,4′-dimethoxytrityl(DMTr) group, a 4-methoxytrityl (MMTr) group, or4-methoxybenzyloxycarbonyl (MCBz) group, or a hydrogen atom; and

represents a binding site to a carbon atom at a 1′-position of anadjacent pentose sugar.
 2. A compound comprising a structural unitrepresented by the following Formula T-1; a structural unit representedby the following Formula D-1 or Formula D-2; and at least one structuralunit derived from any one compound selected from compounds representedby the following Formula E-1 and E-2:

wherein, in Formula T-1, R² represents a hydrogen atom, a halogen atom,or —OR^(O), wherein R^(O) represents a hydrogen atom, an alkyl group, anacetyl group, a phenoxyacetyl group, a pivaloyl group, a benzyl group, a4-methoxybenzyl group, a benzoyl group, a triphenylmethyl group, a4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, a9-phenylxanthenyl group, a trimethylsilyl group, a cyanomethoxymethylgroup, a 2-(cyanoethoxy)ethyl group, or a cyanoethoxymethyl group; Zrepresents a structure represented by any one of Formula B-6 to FormulaB-9; and each of * and ** represents a binding site with anotherstructure, wherein, in Formula D-1 or Formula D-2, R¹ represents analkoxy group, —NR^(N) ₂, a hydroxy group, an aryl group, or an alkylgroup, wherein R^(N) each independently represents a hydrogen atom or analkyl group having 1 to 10 carbon atoms; n represents an integer from 1to 5; R² represents a hydrogen atom, a halogen atom, or —OR^(O), whereinR^(O) represents a hydrogen atom, an alkyl group, an acetyl group, aphenoxyacetyl group, a pivaloyl group, a benzyl group, a 4-methoxybenzylgroup, a benzoyl group, a triphenylmethyl group, a 4,4′-dimethoxytrityl(DMTr) group, a 4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group,a trimethylsilyl group, a cyanomethoxymethyl group, a2-(cyanoethoxy)ethyl group, and a cyanoethoxymethyl group, andpreferably a 4,4′-dimethoxytrityl (DMTr) group; R³ represents a hydrogenatom, an acetyl group, a phenoxyacetyl group, a pivaloyl group, a benzylgroup, a 4-methoxybenzyl group, a benzoyl group, a triphenylmethylgroup, a 4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr)group, a 9-phenylxanthenyl group, a trimethylsilyl group, acyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or acyanoethoxymethyl group; X represents a structure represented by any oneof Formula B-1 to Formula B-5; TfO represents a triflate anion; and ●represents a binding site with another structure, wherein, in FormulaE-1 and E-2, R¹ represents an alkoxy group, —NR^(N) ₂, a hydroxy group,an aryl group, or an alkyl group, wherein R^(N) each independentlyrepresents a hydrogen atom or an alkyl group having 1 to 10 carbonatoms; n represents an integer from 1 to 5; R³ represents a hydrogenatom, an acetyl group, a phenoxyacetyl group, a pivaloyl group, a benzylgroup, a 4-methoxybenzyl group, a benzoyl group, a triphenylmethylgroup, a 4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr)group, a 9-phenylxanthenyl group, a trimethylsilyl group, acyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or acyanoethoxymethyl group; and X represents a structure represented by anyone of Formula B-1 to Formula B-5, wherein, in Formula B-1 to FormulaB-5, R^(T) represents a hydrogen atom, an alkyl group, an alkenyl group,or an alkynyl group; each of R^(pC), R^(pA), and R^(pG) represents atert-butoxycarbonyl group, a benzyloxycarbonyl group, a4,4′-trimethoxytrityl (TMTr) group, a 4,4′-dimethoxytrityl (DMTr) group,a 4-methoxytrityl (MMTr) group, or 4-methoxybenzyloxycarbonyl (MCBz)group; R^(pC2) represents a hydrogen atom; R^(pG2) represents an acetylgroup, a phenoxyacetyl group, a pivaloyl group, a benzyl group, a4-methoxybenzyl group, a benzoyl group, a triphenylmethyl group, a4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, a9-phenylxanthenyl group, a trimethylsilyl group, a trimethylsilylethylgroup, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethyl group, or acyanoethoxymethyl group; R^(pG3) represents a tert-butoxycarbonyl group,a benzyloxycarbonyl group, a 4,4′-trimethoxytrityl (TMTr) group, a4,4′-dimethoxytrityl (DMTr) group, a 4-methoxytrityl (MMTr) group, or4-methoxybenzyloxycarbonyl (MCBz) group, or a hydrogen atom; and

represents a binding site to a carbon atom at a 1′-position of anadjacent pentose sugar, and wherein, in Formula B-6 to Formula B-9,R^(T) represents a hydrogen atom, an alkyl group, an alkenyl group, oran alkynyl group; each of R^(C), R^(A), and R^(G) represents a hydrogenatom; R^(C2) represents a hydrogen atom; and

represents a binding site to a carbon atom at a 1′-position of anadjacent pentose sugar.
 3. The compound according to claim 2, furthercomprising one or both structural units represented by the followingFormula C-1 or Formula C-2:

wherein, in Formula C-1 or Formula C-2, R² represents a hydrogen atom, ahalogen atom, or —OR^(O), wherein R^(O) represents a hydrogen atom, analkyl group, an acetyl group, a phenoxyacetyl group, a pivaloyl group, abenzyl group, a 4-methoxybenzyl group, a benzoyl group, atriphenylmethyl group, a 4,4′-dimethoxytrityl (DMTr) group, a4-methoxytrityl (MMTr) group, a 9-phenylxanthenyl group, atrimethylsilyl group, a cyanomethoxymethyl group, a 2-(cyanoethoxy)ethylgroup, or a cyanoethoxymethyl group; Z represents a structurerepresented by any one of Formula B-6 to Formula B-9; and each of ** and● represents a binding site with another structure, and wherein, inFormula B-6 to Formula B-9, R^(T) represents a hydrogen atom, an alkylgroup, an alkenyl group, or an alkynyl group; each of R^(C), R^(A), andR^(G) represents a hydrogen atom; R^(C2) represents a hydrogen atom; and

represents a binding site to a carbon atom at a 1′-position of anadjacent pentose sugar.
 4. A method of producing a boranophosphateoligomer, comprising condensing the polymerizable compound according toclaim 1.